Tech Company Financing Transactions
Lario Therapeutics Funding Round
The Michael J. Fox Foundation for Parkinson's Research and Wellcome Leap invested in a $2.4 million venture round for Lario Therapeutics. The funding round was announced on 2/19/2026.
Transaction Overview
Company Name
Announced On
2/19/2026
Transaction Type
Debt
Amount
$2,400,000
Round
Undisclosed
Proceeds Purpose
With the proceeds of these awards, Lario is expanding its work in Parkinson's disease and exploring an additional high-priority indication - post-traumatic stress disorder (PTSD).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
137A George Street
Edinburgh, EH2 4JY
UK
Edinburgh, EH2 4JY
UK
Phone
Undisclosed
Website
Email Address
Overview
Lario Therapeutics are developing first-in-class precision medicines as disease modifying treatments for severe neurological disorders including epileptic conditions and Parkinson's disease. Our rapidly advancing pipeline begins with genetically validated targets and promises broad therapeutic potential, with a chance to slow the progression of these devastating early childhood syndromes and adult neurological disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Henning Steinhagen
Chief Scientific Officer
Tom Otis
Co-Founder
Daniel Gill
VP - Finance
Richard Brooks
Browse more venture capital transactions:
Prev: 2/19/2026: Giggle venture capital transaction
Next: 2/19/2026: Kombo venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs